EGFR and non-small cell lung carcinoma: Afatinib achieved durable responses in a small number of NSCLC patients with specific EGFR ex20ins mutations.[14–16] Both Fang et al[36] and Qin et al[35] reported that osimertinib could effectively inhibit specific subtypes of EGFR ex20ins mutations.